[
  {
    "ts": null,
    "headline": "This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence",
    "summary": "Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom. The sector’s relative earnings growth averaged just 6% annually over that stretch, trailing the S&P 500‘s 15%, but signs of stabilization emerged ... This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence",
    "url": "https://finnhub.io/api/news?id=229948e39b9a5dea52d7dee65c8a4916aff509b51ab9e65e86f189114ec68916",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765390789,
      "headline": "This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence",
      "id": 137749921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom. The sector’s relative earnings growth averaged just 6% annually over that stretch, trailing the S&P 500‘s 15%, but signs of stabilization emerged ... This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence",
      "url": "https://finnhub.io/api/news?id=229948e39b9a5dea52d7dee65c8a4916aff509b51ab9e65e86f189114ec68916"
    }
  },
  {
    "ts": null,
    "headline": "ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL",
    "summary": "AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.",
    "url": "https://finnhub.io/api/news?id=0d4c9e90ad98ee5734c3dd61c9a8805dbb5ace8682636a8e60dc7877ce6b999c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765388442,
      "headline": "ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL",
      "id": 137749922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.",
      "url": "https://finnhub.io/api/news?id=0d4c9e90ad98ee5734c3dd61c9a8805dbb5ace8682636a8e60dc7877ce6b999c"
    }
  },
  {
    "ts": null,
    "headline": "DLocal And 2 Other Stocks That May Be Priced Below Intrinsic Value",
    "summary": "As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.",
    "url": "https://finnhub.io/api/news?id=c75a79175ff4ce1cfec18350079e37bae2cc7e9621723a97c767218fa7b66abe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765388285,
      "headline": "DLocal And 2 Other Stocks That May Be Priced Below Intrinsic Value",
      "id": 137749923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.",
      "url": "https://finnhub.io/api/news?id=c75a79175ff4ce1cfec18350079e37bae2cc7e9621723a97c767218fa7b66abe"
    }
  },
  {
    "ts": null,
    "headline": "At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High Income ETFs Today",
    "summary": "The Global X SuperDividend ETF (NYSEARCA:SDIV) generates its 8% yield by investing in 100 of the highest dividend-yielding equities across global markets. The fund holds stocks from developed and emerging markets spanning telecommunications, energy, materials, financials, and real estate. Income comes directly from dividends paid by underlying companies, making SDIV’s distributions entirely dependent on whether ... At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High In",
    "url": "https://finnhub.io/api/news?id=b06f572511a2683e56ee3d41abb2779256d6a0b6efee380b9ac78f055b530b20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765383194,
      "headline": "At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High Income ETFs Today",
      "id": 137749924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Global X SuperDividend ETF (NYSEARCA:SDIV) generates its 8% yield by investing in 100 of the highest dividend-yielding equities across global markets. The fund holds stocks from developed and emerging markets spanning telecommunications, energy, materials, financials, and real estate. Income comes directly from dividends paid by underlying companies, making SDIV’s distributions entirely dependent on whether ... At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High In",
      "url": "https://finnhub.io/api/news?id=b06f572511a2683e56ee3d41abb2779256d6a0b6efee380b9ac78f055b530b20"
    }
  },
  {
    "ts": null,
    "headline": "Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls",
    "summary": "Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=b0e842c8ea1c5cce103534f29518eb9c1f9f66e4ff0a34b2c3af85a742deb45c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765377600,
      "headline": "Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls",
      "id": 137749925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=b0e842c8ea1c5cce103534f29518eb9c1f9f66e4ff0a34b2c3af85a742deb45c"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More",
    "url": "https://finnhub.io/api/news?id=894e11783022f0ab66ac1975da95caa3723a9bc1b92d20095a49fcd3e00116dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765375761,
      "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More",
      "id": 137749926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More",
      "url": "https://finnhub.io/api/news?id=894e11783022f0ab66ac1975da95caa3723a9bc1b92d20095a49fcd3e00116dc"
    }
  },
  {
    "ts": null,
    "headline": "HSBC highlights one pharma stock to buy and one to sell for 2026",
    "summary": "Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.",
    "url": "https://finnhub.io/api/news?id=577018d29150f231ee24cc4eae8caf159a420b69210012fe907d5903f28b1516",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765373818,
      "headline": "HSBC highlights one pharma stock to buy and one to sell for 2026",
      "id": 137749927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.",
      "url": "https://finnhub.io/api/news?id=577018d29150f231ee24cc4eae8caf159a420b69210012fe907d5903f28b1516"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Upgrades AbbVie (ABBV)",
    "summary": "HSBC Upgrades AbbVie (ABBV)",
    "url": "https://finnhub.io/api/news?id=928c2f340d51a8477408b0b82bc53ec1aabedabb7a14a0cb150641fa3cbba606",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765368184,
      "headline": "HSBC Upgrades AbbVie (ABBV)",
      "id": 137747160,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=928c2f340d51a8477408b0b82bc53ec1aabedabb7a14a0cb150641fa3cbba606"
    }
  },
  {
    "ts": null,
    "headline": "3 Prominent Stocks Estimated To Be Trading At Up To 38.4% Below Intrinsic Value",
    "summary": "As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.",
    "url": "https://finnhub.io/api/news?id=316c65f193dc05044f993c4a9800471dacd1afad3305bd37c35f5247d964a059",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765366678,
      "headline": "3 Prominent Stocks Estimated To Be Trading At Up To 38.4% Below Intrinsic Value",
      "id": 137749928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.",
      "url": "https://finnhub.io/api/news?id=316c65f193dc05044f993c4a9800471dacd1afad3305bd37c35f5247d964a059"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
    "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
    "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765362409,
      "headline": "AstraZeneca: A Rare Compound Growth Opportunity In Biopharma",
      "id": 137747724,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307043297/image_1307043297.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about AZN stock here.",
      "url": "https://finnhub.io/api/news?id=7607e031783e690b2011e6797309b77b7a7084aa1403fc9ee0fe0c21f814be29"
    }
  }
]